Navigation Links
Kendle Invites You to Attend its First Quarter 2008 Earnings Conference Call and Webcast
Date:4/24/2008


CINCINNATI, April 24 /PRNewswire-FirstCall/ --

CALL DATE: Wednesday, May 7, 2008

TIME: 9:30 a.m. Eastern Time

HOST: Dr. Candace Kendle, Chairman and CEO

Kendle (Nasdaq: KNDL) will conduct a telephone conference call and simultaneous webcast on Wednesday, May 7 at 9:30 a.m. Eastern Time to discuss its financial results for the First Quarter ended March 31, 2008. A question and answer session will follow.

Webcast Instructions

To access the live webcast, go to http://www.kendle.com or http://www.videonewswire.com/event.asp?id=47950. Instructions for accessing the webcast are provided at both sites. The webcast will be archived at http://www.kendle.com (click on "Investors" and then "Events & Presentations") shortly after the call for on-demand replay through 5 p.m. Eastern Time on June 6, 2008. Please note that webcast participants will not be able to ask questions.

System requirements for the webcast include Windows Media Player software and at least a 28.8 Kbps connection to the Internet. Media Player is downloadable at no charge from http://www.microsoft.com/windows/windowsmedia/default.aspx.

Conference Call Instructions

To register (RSVP) for the telephone conference call, U.S. and Canadian participants should dial (800) 223-7104. Participants outside North America should dial (706) 645-6519.

To participate in the telephone conference call, interested parties in the United States and Canada should dial (800) 399-0069. Participants outside North America should dial (706) 643-3694. A replay will be available through 5 p.m. Eastern Time on June 6 by dialing (706) 645-9291 and entering conference ID number 41241978.

About Kendle

Kendle (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services we offer experience spanning 90 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges. Kendle was named "Top CRO to Work With" in the Thomson CenterWatch 2007 survey of U.S. investigative sites and "Best CRO" for 2007 and 2006 by leading global pharmaceutical publication Scrip World Pharmaceutical News.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202, United States or from the company's Web site at http://www.kendle.com

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )


'/>"/>
SOURCE Kendle
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
2. Kendle Leaders Adopt 10b5-1 Trading Plans
3. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
4. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
5. Kendle to Present at the Wachovia 2008 Healthcare Conference
6. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
7. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
8. Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
9. Kendle to Present at the Natixis Bleichroeder Hidden Gems Conference
10. Kendle to Present at the UBS Global Life Sciences Conference
11. Kendle to Present at Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... MONTREAL , Feb. 20, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: ... as President and CEO and Fabrice Orecchioni, the company,s COO, has ... as COO over the past four years, Fabrice has overseen the ... Sarnia and the management of the Mitsui JV.  Fabrice ... for the proposed China JV. ...
(Date:2/20/2017)... , Feb. 20, 2017 This report analyzes the ... following Product Types: Xylanase, Amylase, Cellulase, and Others. The report ... , Japan , Europe ... America , and Rest of World. ... estimates and forecasts are provided for the period 2015 through ...
(Date:2/20/2017)... ... February 20, 2017 , ... Cancer ... “Crosswalk Insight: Oncology™” (Crosswalk), a unique precision medicine knowledge visualization and decision support ... accessed through Inspirata’s diagnostic cockpit and is downloadable as an app for any ...
(Date:2/20/2017)... Philadelphia, PA (PRWEB) , ... ... ... technologies to improve therapeutic success among radiotherapy patients, prevent chest wall collapses ... for femur fracture alignments will receive a total of $600,000 in funding ...
Breaking Biology Technology:
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 ... growing at a compound annual growth rate (CAGR) of 24.0% ... global markets for synthetic biology. - Analyses of global market ... of compound annual growth rates (CAGRs) through 2021. - Coverage ...
(Date:2/7/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... present at the LEERINK Partners 6th Annual Global Healthcare ... Wednesday, February 15, 2017 at 10 a.m. Eastern Time. ... can be accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
Breaking Biology News(10 mins):